Journal article
Infection, Inflammation, and Lung Function Decline in Infants with Cystic Fibrosis
Naveen Pillarisetti, Elizabeth Williamson, Barry Linnane, Billy Skoric, Colin F Robertson, Phil Robinson, John Massie, Graham L Hall, Peter Sly, Stephen Stick, Sarath Ranganathan
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | AMER THORACIC SOC | Published : 2011
Abstract
RATIONALE: Better understanding of evolution of lung function in infants with cystic fibrosis (CF) and its association with pulmonary inflammation and infection is crucial in informing both early intervention studies aimed at limiting lung damage and the role of lung function as outcomes in such studies. OBJECTIVES: To describe longitudinal change in lung function in infants with CF and its association with pulmonary infection and inflammation. METHODS: Infants diagnosed after newborn screening or clinical presentation were recruited prospectively. FVC, forced expiratory volume in 0.5 seconds (FEV(0.5)), and forced expiratory flows at 75% of exhaled vital capacity (FEF(75)) were measured usi..
View full abstractGrants
Funding Acknowledgements
Supported by grants from the United States Cystic Fibrosis Foundation, the National Health and Medical Research Council, Australia, and the Australian Cystic Fibrosis Research Trust; and by the Royal Children's Hospital Melbourne Cystic Fibrosis Research Trust (N.P.).N.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. E. W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B. L. received institutional grant support form the National Health and Medical Research Council (NHMRC). B. S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. C. F. R. received institutional grant support form the NHMRC. P. R. received institutional grant support form the NHMRC. J.M. received institutional grant support from the Australian CF Research Trust. G. L. H. received institutional grant support form the NHMRC. P. S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S. S. received institutional grant support from the NHMRC and USCF Therapeutics. He was a Board member of Inspire Pharmaceuticals and Vertex Pharmaceuticals. S. R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.